Skip to main content
Premium Trial:

Request an Annual Quote

ChromaCode Raises Additional $10M in Series C Round

NEW YORK — ChromaCode said on Tuesday that it has raised an additional $10 million in Series C funding, bringing the total value of the financing round to $38 million.

The Carlsbad, California-based firm said it will use the cash infusion to continue development of its high-definition PCR technology, a software and assay platform that uses existing real-time PCR instruments and digital signal processing to improve molecular analyses. The platform is the basis for ChromaCode's multi-drug resistance and tick-borne pathogens multiplex panels, as well as its recently launched SARS-CoV-2 assay.  

ChromaCode said the Series C money will also be used to further its global expansion, with an eye toward resource-limited communities in low- to middle-income nations.

The new investment comes from Adjuvant Capital, which has also received a seat on ChromaCode's board. ChromaCode previously raised $28 million through the Series C round in December, $12 million in Series B funding in 2017, and $2.5 million a Series A funding in 2015.

The Scan

Foxtail Millet Pangenome, Graph-Based Reference Genome

Researchers in Nature Genetics described their generation of a foxtail millet pangenome, which they say can help in crop trait improvement.

Protein Length Distribution Consistent Across Species

An analysis in Genome Biology compares the lengths of proteins across more than 2,300 species, finding similar length distributions.

Novel Genetic Loci Linked to Insulin Resistance in New Study

A team reports in Nature Genetics that it used glucose challenge test data to home in on candidate genes involved in GLUT4 expression or trafficking.

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.